These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 28766389)

  • 41. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience.
    Bahap-Kara M; Duran E; Bayraktar-Ekincioglu A; Karadag O
    Intern Emerg Med; 2023 Apr; 18(3):791-799. PubMed ID: 36826744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.
    Beum PV; Kennedy AD; Taylor RP
    J Immunol Methods; 2004 Jun; 289(1-2):97-109. PubMed ID: 15251416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany.
    Otremba B; Borchardt J; Kuske A; Hollnagel-Schmitz M; Losch FO
    Future Oncol; 2020 May; 16(15):1001-1012. PubMed ID: 32286864
    [No Abstract]   [Full Text] [Related]  

  • 45. SB2: An Infliximab Biosimilar.
    Lamb YN; Scott LJ; Deeks ED
    BioDrugs; 2017 Oct; 31(5):461-464. PubMed ID: 28803431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
    Yoo DH; Oh C; Hong S; Park W
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab.
    Stewart M; Malkovska V; Krishnan J; Lessin L; Barth W
    Ann Rheum Dis; 2001 Sep; 60(9):892-3. PubMed ID: 11502618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.
    Poddubnaya IV; Alekseev SM; Kaplanov KD; Lukavetskyy LM; Rekhtman GB; Dolai TK; Attili VSS; Bermúdez CD; Isaev AA; Chernyaeva EV; Ivanov RA
    Hematol Oncol; 2020 Feb; 38(1):67-73. PubMed ID: 31724191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
    Zhao S; Chadwick L; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rituximab for rheumatoid arthritis.
    Palylyk-Colwell E; McGahan L
    Issues Emerg Health Technol; 2006 Sep; (89):1-4. PubMed ID: 17014062
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20
    Jiang B; Ke X; Zhang Q; Xu W; Su H; Huang J; Zhang M; Wang H; Jin C; Zhu J; Liu L; Cai Z; Zhao X; Zhou J; Zhang X; Liu J; Zhou H; Yu J; Sun X; Qi J; Qiu L
    Sci Rep; 2020 Jul; 10(1):11676. PubMed ID: 32669656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
    Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting.
    Pavlych V; Di Muzio C; Alunno A; Carubbi F
    Front Med (Lausanne); 2020; 7():534. PubMed ID: 33015092
    [No Abstract]   [Full Text] [Related]  

  • 54. Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA.
    Shelbaya A; Kelton JM; Thompson J; Alvir JM; Maculaitis MC; Yang J
    Future Oncol; 2021 Oct; 17(30):3941-3950. PubMed ID: 34259584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?
    Chaudhry M; Cheson BD
    Expert Rev Hematol; 2015 Dec; 8(6):733-42. PubMed ID: 26368831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab.
    Łosińska K; Korkosz M; Pripp AH; Haugeberg G
    Rheumatol Int; 2023 May; 43(5):881-888. PubMed ID: 36922417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma.
    Panayi GS; Hainsworth JD; Looney RJ; Keystone EC
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii18-ii20. PubMed ID: 15851523
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of switching between rituximab biosimilars in onco-hematology.
    Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
    Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.
    Cobb P; Niederwieser D; Cohen S; Hamm C; Burmester G; Seo N; Lehto SG; Hanes V
    Immunotherapy; 2022 Jun; 14(9):727-740. PubMed ID: 35543293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.